Research progress in molecular targeted therapy for inflammatory bowel disease

作者：Nan Liu, Chengye Pan, Lishuai Qu · 发表于：Journal of Translational Medicine · 年份：2025 · DOI：10.1186/s12967-025-07385-3 · 被引用次数：5 · 研究领域：Inflammatory Bowel Disease、Liver Diseases and Immunity、Rheumatoid Arthritis Research and Therapies

INTRODUCTION: Inflammatory Bowel Disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is increasingly prevalent in China. Traditional treatments often have limited efficacy and safety, whereas molecular targeted therapies provide more precise and effective options with fewer adverse effects. The pathogenesis of IBD involves dysregulated inflammatory pathways including NF-κB, IL-23/Th17, and TGF-β. Major targeted therapies include TNF-α inhibitors, which are effective for induction and maintenance of remission (particularly when combined with immunomodulators), integrin antagonists, JAK inhibitors, limited IL-6 pathway inhibitors, and emerging agents targeting additional pathways. Biomarkers such as miR-21 and transcriptomic signatures support personalized treatment selection. Molecular targeted therapy has evolved from single-target strategies to multi-pathway modulation, improving clinical management. Nevertheless, challenges persist, including primary non-response, secondary loss of response, and safety risks. Further research is needed to refine sequencing strategies, integrate validated biomarkers into clinical practice, and optimize risk-benefit profiles. BACKGROUND: The global burden of IBD continues to rise, particularly in newly industrialized regions such as China, where urbanization and lifestyle changes have accelerated incidence rates. Conventional therapies-aminosalicylates, corticosteroids, and traditional immunomodulators-often fail to ...